Index of artpub/2023/303869/

John, Thomas
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC : Updated Analysis From the Phase 3 ADAURA Trial
2023
https://ddd.uab.cat/record/303869